Literature DB >> 28237214

Advancing Value Assessment in the United States: A Multistakeholder Perspective.

Corinna Sorenson1, Gabriela Lavezzari2, Gregory Daniel2, Randy Burkholder3, Marc Boutin4, Edmund Pezalla5, Gillian Sanders6, Mark McClellan2.   

Abstract

Rising costs without perceived proportional improvements in quality and outcomes have motivated fundamental shifts in health care delivery and payment to achieve better value. Aligned with these efforts, several value assessment frameworks have been introduced recently to help providers, patients, and payers better understand the potential value of drugs and other interventions and make informed decisions about their use. Given their early stage of development, it is imperative to evaluate these efforts on an ongoing basis to identify how best to support and improve them moving forward. This article provides a multistakeholder perspective on the key limitations and opportunities posed by the current value assessment frameworks and areas of and actions for improvement. In particular, we outline 10 fundamental guiding principles and associated strategies that should be considered in subsequent iterations of the existing frameworks or by emerging initiatives in the future. Although value assessment frameworks may not be able to meet all the needs and preferences of stakeholders, we contend that there are common elements and potential next steps that can be supported to advance value assessment in the United States.
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  health care decision makers; standards; value assessment; value for money

Mesh:

Year:  2017        PMID: 28237214     DOI: 10.1016/j.jval.2016.11.030

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  6 in total

Review 1.  The role of biosimilars in value-based oncology care.

Authors:  Kashyap B Patel; Luiz H Arantes; Wing Yu Tang; Selwyn Fung
Journal:  Cancer Manag Res       Date:  2018-10-17       Impact factor: 3.989

Review 2.  Value-based medicine in oncology: the importance of perspective in the emerging value frameworks.

Authors:  Alessandro Gonçalves Campolina
Journal:  Clinics (Sao Paulo)       Date:  2018-12-10       Impact factor: 2.365

3.  Assessing value in health care: using an interpretive classification system to understand existing practices based on a systematic review.

Authors:  Brayan V Seixas; François Dionne; Tania Conte; Craig Mitton
Journal:  BMC Health Serv Res       Date:  2019-08-13       Impact factor: 2.655

4.  Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment.

Authors:  Jason C Hsu; Jia-Yu Lin; Peng-Chan Lin; Yang-Cheng Lee
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

5.  A Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT® Re-usable in the Nordics and Benelux.

Authors:  Gustaf Ortsäter; Fredrik Borgström; Stéphane Soulard; Carolin Miltenburger
Journal:  Adv Ther       Date:  2019-10-17       Impact factor: 3.845

6.  Stakeholder-Engaged Derivation of Patient-Informed Value Elements.

Authors:  Susan dosReis; Beverly Butler; Juan Caicedo; Annie Kennedy; Yoon Duk Hong; Chengchen Zhang; Julia F Slejko
Journal:  Patient       Date:  2020-10       Impact factor: 3.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.